Speaker Profile

M.D., Ph.D., Medical Director, University of South Alabama

Biography
Thuy Phung, MD, PhD is associate professor and medical director of molecular pathology & dermatopathology at the University of South Alabama. She has been spearheading efforts to enhance molecular diagnostics for cancer patients in underserved areas in the Gulf Coast region by establishing rapid single-gene testing as well as actionable, cost-effective next generation sequencing (NGS) assays. She is the lead author of Pediatric Dermatopathology, a comprehensive textbook in the field. Dr. Phung is passionate about global health. She co-founded the award-winning Vascular Anomalies Center in Ho Chi Minh City, Vietnam, which cares for thousands of underserved children with vascular birthmarks, and is leading efforts to establish molecular diagnostics for these disorders.


Clinical Dx Showcase:
University of South Alabama

University of South Alabama is an academic healthcare system comprised of university hospital, women & children's hospital, cancer institute and affiliated medical clinics that provide quality healthcare services to communities across the Gulf Coast region.

Establishing Molecular Testing in Communities
Molecular diagnostics provide important genetic information for informed precision cancer care. However, molecular testing, such as broad-panel testing, remains underutilized in oncology practices in community/small laboratory setting. The presentation’s aim is to explore and address the gap in molecular testing in underserved communities.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative